| 2,4-thiazolidinedione | The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Lurasidone. | Investigational |
| 2,5-Dimethoxy-4-ethylamphetamine | Lurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. | Experimental, Illicit |
| 3,4-Methylenedioxyamphetamine | Lurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. | Experimental, Illicit |
| 3,4-Methylenedioxymethamphetamine | Lurasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine. | Experimental, Illicit |
| 4-Bromo-2,5-dimethoxyamphetamine | Lurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. | Experimental, Illicit |
| 7-Nitroindazole | The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lurasidone. | Experimental |
| Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Acepromazine | The risk or severity of adverse effects can be increased when Acepromazine is combined with Lurasidone. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Aceprometazine is combined with Lurasidone. | Approved |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone. | Withdrawn |
| Adipiplon | The risk or severity of adverse effects can be increased when adipiplon is combined with Lurasidone. | Investigational |
| Agomelatine | The risk or severity of adverse effects can be increased when Agomelatine is combined with Lurasidone. | Approved, Investigational |
| AICA ribonucleotide | The therapeutic efficacy of Aicar can be decreased when used in combination with Lurasidone. | Experimental |
| Alfaxalone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone. | Vet Approved |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Lurasidone. | Approved, Illicit |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Sage 547. | Investigational |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone. | Approved, Investigational |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone. | Approved |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Lurasidone. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone. | Approved, Illicit, Investigational |
| Amantadine | The therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone. | Approved |
| Amiodarone | The serum concentration of Lurasidone can be increased when it is combined with Amiodarone. | Approved, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride. | Approved, Investigational |
| Amitriptyline | The risk or severity of adverse effects can be increased when Lurasidone is combined with Amitriptyline. | Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide. | Experimental |
| Amphetamine | Lurasidone may decrease the stimulatory activities of Amphetamine. | Approved, Illicit |
| Apomorphine | The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Aprepitant | The serum concentration of Lurasidone can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Aripiprazole | The serum concentration of Aripiprazole can be increased when it is combined with Lurasidone. | Approved, Investigational |
| Articaine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone. | Approved |
| Atazanavir | The serum concentration of Lurasidone can be increased when it is combined with Atazanavir. | Approved, Investigational |
| Atomoxetine | The serum concentration of Lurasidone can be increased when it is combined with Atomoxetine. | Approved |
| Azelastine | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Azelastine. | Approved |
| Baclofen | The risk or severity of adverse effects can be increased when Lurasidone is combined with Baclofen. | Approved |
| Balaglitazone | The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lurasidone. | Investigational |
| Barbital | The risk or severity of adverse effects can be increased when Barbital is combined with Lurasidone. | Illicit |
| Benperidol | The risk or severity of adverse effects can be increased when Lurasidone is combined with Benperidol. | Investigational |
| Benzocaine | The risk or severity of adverse effects can be increased when Benzocaine is combined with Lurasidone. | Approved |
| Benzphetamine | Lurasidone may decrease the stimulatory activities of Benzphetamine. | Approved, Illicit |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lurasidone. | Approved |
| Bexarotene | The serum concentration of Lurasidone can be decreased when it is combined with Bexarotene. | Approved, Investigational |
| Boceprevir | The serum concentration of Lurasidone can be increased when it is combined with Boceprevir. | Withdrawn |
| Bortezomib | The serum concentration of Lurasidone can be increased when it is combined with Bortezomib. | Approved, Investigational |
| Bosentan | The serum concentration of Lurasidone can be decreased when it is combined with Bosentan. | Approved, Investigational |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone. | Approved, Illicit |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Brompheniramine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Lurasidone is combined with Brotizolam. | Approved, Withdrawn |
| Buformin | The therapeutic efficacy of Buformin can be decreased when used in combination with Lurasidone. | Withdrawn |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lurasidone. | Approved, Investigational |
| Buprenorphine | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Buspirone | The risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone. | Approved, Illicit |
| Butalbital | The risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital. | Approved, Illicit |
| Butethal | The risk or severity of adverse effects can be increased when Butethal is combined with Lurasidone. | Approved, Illicit |
| Butorphanol | The risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone. | Approved, Illicit, Vet Approved |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone. | Approved |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone. | Approved |
| Carbamazepine | The serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine. | Approved, Investigational |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Lurasidone. | Illicit, Vet Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol. | Approved |
| Castanospermine | The therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone. | Experimental |
| Ceritinib | The serum concentration of Lurasidone can be increased when it is combined with Ceritinib. | Approved |
| Cetirizine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lurasidone. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Chlormezanone is combined with Lurasidone. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lurasidone. | Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine. | Approved |
| Chlorphentermine | Lurasidone may decrease the stimulatory activities of Chlorphentermine. | Illicit, Withdrawn |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone. | Approved, Vet Approved |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone. | Approved |
| Chlorprothixene | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lurasidone. | Approved, Withdrawn |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone. | Approved |
| Ciglitazone | The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone. | Experimental |
| Cinchocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Lurasidone. | Approved, Vet Approved |
| Citalopram | The risk or severity of adverse effects can be increased when Citalopram is combined with Lurasidone. | Approved |
| Clarithromycin | The serum concentration of Lurasidone can be increased when it is combined with Clarithromycin. | Approved |
| Clemastine | The serum concentration of Lurasidone can be increased when it is combined with Clemastine. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium. | Approved |
| Clobazam | The risk or severity of adverse effects can be increased when Lurasidone is combined with Clobazam. | Approved, Illicit |
| Clomipramine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam. | Approved, Illicit |
| Clonidine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine. | Approved |
| Clorazepate | The risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone. | Approved, Illicit |
| Clotrimazole | The serum concentration of Lurasidone can be increased when it is combined with Clotrimazole. | Approved, Vet Approved |
| Clozapine | The risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone. | Approved |
| Cobicistat | The serum concentration of Lurasidone can be increased when it is combined with Cobicistat. | Approved |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Lurasidone. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone. | Approved, Illicit |
| Conivaptan | The serum concentration of Lurasidone can be increased when it is combined with Conivaptan. | Approved, Investigational |
| Crizotinib | The serum concentration of Lurasidone can be increased when it is combined with Crizotinib. | Approved |
| Cyclizine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone. | Approved |
| Cyclosporine | The serum concentration of Lurasidone can be increased when it is combined with Cyclosporine. | Approved, Investigational, Vet Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine. | Approved |
| Dabrafenib | The serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Lurasidone. | Approved |
| Dapoxetine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine. | Investigational |
| Darunavir | The serum concentration of Lurasidone can be increased when it is combined with Darunavir. | Approved |
| Dasatinib | The serum concentration of Lurasidone can be increased when it is combined with Dasatinib. | Approved, Investigational |
| Deferasirox | The serum concentration of Lurasidone can be decreased when it is combined with Deferasirox. | Approved, Investigational |
| Delavirdine | The serum concentration of Lurasidone can be increased when it is combined with Delavirdine. | Approved |
| Deoxyspergualin | The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lurasidone. | Investigational |
| Deramciclane | The risk or severity of adverse effects can be increased when deramciclane is combined with Lurasidone. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone. | Approved |
| Desipramine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine. | Approved |
| Desloratadine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine. | Approved, Investigational |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lurasidone. | Approved |
| Dexamethasone | The serum concentration of Lurasidone can be decreased when it is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lurasidone. | Approved, Vet Approved |
| Dextroamphetamine | Lurasidone may decrease the stimulatory activities of Dextroamphetamine. | Approved, Illicit |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone. | Approved |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Lurasidone. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lurasidone. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Lurasidone. | Approved |
| Diazepam | The risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone. | Approved, Illicit, Vet Approved |
| Diethylpropion | Lurasidone may decrease the stimulatory activities of Diethylpropion. | Approved, Illicit |
| Difenoxin | The risk or severity of adverse effects can be increased when Lurasidone is combined with Difenoxin. | Approved, Illicit |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone. | Approved, Illicit |
| Dihydroergotamine | The serum concentration of Lurasidone can be increased when it is combined with Dihydroergotamine. | Approved |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lurasidone. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lurasidone. | Experimental, Illicit |
| Diltiazem | The serum concentration of Lurasidone can be increased when it is combined with Diltiazem. | Approved |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate. | Approved |
| Diphenhydramine | The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone. | Approved, Illicit |
| Disopyramide | Lurasidone may increase the QTc-prolonging activities of Disopyramide. | Approved |
| Dofetilide | The serum concentration of Dofetilide can be increased when it is combined with Lurasidone. | Approved |
| Dopamine | Dopamine may increase the hypotensive activities of Lurasidone. | Approved |
| Doxepin | The risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin. | Approved |
| Doxycycline | The serum concentration of Lurasidone can be increased when it is combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved, Vet Approved |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved, Illicit |
| Dronedarone | The serum concentration of Lurasidone can be increased when it is combined with Dronedarone. | Approved |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved, Vet Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Drotebanol is combined with Lurasidone. | Experimental, Illicit |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone. | Approved |
| Duloxetine | The risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone. | Approved |
| Ecgonine | The risk or severity of adverse effects can be increased when Ecgonine is combined with Lurasidone. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam. | Investigational |
| Efavirenz | The serum concentration of Lurasidone can be decreased when it is combined with Efavirenz. | Approved, Investigational |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone. | Approved, Investigational |
| Eltanolone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Pregnanolone. | Investigational |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone. | Approved |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Lurasidone. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone. | Approved, Investigational |
| Enzalutamide | The serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide. | Approved |
| Epinephrine | Epinephrine may increase the hypotensive activities of Lurasidone. | Approved, Vet Approved |
| Ergoloid mesylate | The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone. | Approved |
| Ergonovine | The risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone. | Approved |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone. | Approved |
| Erythromycin | The serum concentration of Lurasidone can be increased when it is combined with Erythromycin. | Approved, Vet Approved |
| Escitalopram | The risk or severity of adverse effects can be increased when Escitalopram is combined with Lurasidone. | Approved, Investigational |
| Eslicarbazepine acetate | The serum concentration of Lurasidone can be decreased when it is combined with Eslicarbazepine acetate. | Approved |
| Estazolam | The risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone. | Approved, Illicit |
| Eszopiclone | The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone. | Approved |
| Ethanol | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lurasidone. | Approved, Illicit, Withdrawn |
| Ethosuximide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin. | Approved |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lurasidone. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lurasidone. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lurasidone. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Etidocaine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Etifoxine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Lurasidone is combined with Etizolam. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Lurasidone. | Approved |
| Etoperidone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Lurasidone. | Illicit, Vet Approved |
| Etravirine | The serum concentration of Lurasidone can be decreased when it is combined with Etravirine. | Approved |
| Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Ezogabine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ezogabine. | Approved |
| Felbamate | The risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate. | Approved |
| Fencamfamine | The risk or severity of adverse effects can be increased when Fencamfamine is combined with Lurasidone. | Approved, Illicit, Withdrawn |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone. | Approved, Illicit, Investigational, Vet Approved |
| Fexofenadine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine. | Approved |
| Flibanserin | The serum concentration of Flibanserin can be increased when it is combined with Lurasidone. | Approved |
| Fluconazole | The serum concentration of Lurasidone can be increased when it is combined with Fluconazole. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Fludiazepam is combined with Lurasidone. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lurasidone. | Approved, Illicit |
| Fluoxetine | The risk or severity of adverse effects can be increased when Fluoxetine is combined with Lurasidone. | Approved, Vet Approved |
| Flupentixol | The risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone. | Approved, Withdrawn |
| Fluphenazine | The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone. | Approved |
| Flurazepam | The risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lurasidone. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The serum concentration of Lurasidone can be increased when it is combined with Fluvoxamine. | Approved, Investigational |
| Fosamprenavir | The serum concentration of Lurasidone can be increased when it is combined with Fosamprenavir. | Approved |
| Fosaprepitant | The serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant. | Approved |
| Fosphenytoin | The serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Fospropofol is combined with Lurasidone. | Approved, Illicit |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone. | Approved, Investigational |
| Fusidic Acid | The serum concentration of Lurasidone can be increased when it is combined with Fusidic Acid. | Approved |
| Gabapentin | The risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Lurasidone is combined with gabapentin enacarbil. | Approved |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lurasidone. | Approved, Illicit |
| Gepirone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Gepirone. | Investigational |
| Glibornuride | The therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone. | Withdrawn |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lurasidone. | Approved |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone. | Approved |
| Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone. | Approved |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone. | Approved |
| Glutethimide | The risk or severity of adverse effects can be increased when Glutethimide is combined with Lurasidone. | Approved, Illicit |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone. | Approved |
| Guanfacine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine. | Approved, Investigational |
| Gusperimus | The therapeutic efficacy of Gusperimus can be decreased when used in combination with Lurasidone. | Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Halazepam is combined with Lurasidone. | Approved, Illicit, Withdrawn |
| Haloperidol | The risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Halothane is combined with Lurasidone. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Heroin is combined with Lurasidone. | Approved, Illicit |
| Hexobarbital | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Lurasidone. | Approved |
| Hydrocodone | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone. | Approved, Illicit |
| Hydroxyamphetamine | Lurasidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide. | Approved |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved |
| Idelalisib | The serum concentration of Lurasidone can be increased when it is combined with Idelalisib. | Approved |
| Iloperidone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone. | Approved |
| Imatinib | The serum concentration of Lurasidone can be increased when it is combined with Imatinib. | Approved |
| Imipramine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine. | Investigational, Withdrawn |
| Indinavir | The serum concentration of Lurasidone can be increased when it is combined with Indinavir. | Approved |
| Insulin Aspart | The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone. | Approved |
| Insulin Detemir | The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lurasidone. | Approved |
| Insulin Glargine | The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone. | Approved |
| Insulin Glulisine | The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lurasidone. | Approved |
| Insulin Lispro | The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone. | Approved |
| Insulin Pork | The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone. | Approved |
| Isavuconazonium | The serum concentration of Lurasidone can be increased when it is combined with Isavuconazonium. | Approved, Investigational |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Lurasidone. | Approved, Vet Approved |
| Isradipine | The serum concentration of Lurasidone can be increased when it is combined with Isradipine. | Approved |
| Itraconazole | The serum concentration of Lurasidone can be increased when it is combined with Itraconazole. | Approved, Investigational |
| Ivacaftor | The serum concentration of Lurasidone can be increased when it is combined with Ivacaftor. | Approved |
| Ketamine | The risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone. | Approved, Vet Approved |
| Ketazolam | The risk or severity of adverse effects can be increased when Ketazolam is combined with Lurasidone. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Lurasidone. | Approved |
| Ketoconazole | The serum concentration of Lurasidone can be increased when it is combined with Ketoconazole. | Approved, Investigational |
| Lamotrigine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine. | Approved, Investigational |
| Levetiracetam | The risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam. | Approved, Investigational |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lurasidone. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine. | Approved |
| Levodopa | The therapeutic efficacy of Levodopa can be decreased when used in combination with Lurasidone. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lurasidone. | Approved |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lurasidone. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone. | Approved |
| Lidocaine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Lurasidone. | Approved, Vet Approved |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone. | Approved |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone. | Approved, Investigational |
| Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone. | Approved |
| Lisdexamfetamine | Lurasidone may decrease the stimulatory activities of Lisdexamfetamine. | Approved, Investigational |
| Lithium | Lithium may increase the neurotoxic activities of Lurasidone. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Lurasidone is combined with Lofentanil. | Illicit |
| Lomitapide | The serum concentration of Lomitapide can be increased when it is combined with Lurasidone. | Approved |
| Lopinavir | The serum concentration of Lurasidone can be increased when it is combined with Lopinavir. | Approved |
| Loratadine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone. | Approved |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone. | Approved |
| Lovastatin | The serum concentration of Lurasidone can be increased when it is combined with Lovastatin. | Approved, Investigational |
| Loxapine | The risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone. | Approved |
| Luliconazole | The serum concentration of Lurasidone can be increased when it is combined with Luliconazole. | Approved |
| Lumacaftor | The serum concentration of Lurasidone can be decreased when it is combined with Lumacaftor. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved, Vet Approved |
| Maprotiline | The risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline. | Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine. | Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Melatonin is combined with Lurasidone. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Melperone. | Approved |
| Mephedrone | Lurasidone may decrease the stimulatory activities of Mephedrone. | Investigational |
| Mephentermine | Lurasidone may decrease the stimulatory activities of Mephentermine. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Mepivacaine is combined with Lurasidone. | Approved, Vet Approved |
| Meprobamate | The risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone. | Approved, Illicit |
| Mequitazine | Lurasidone may increase the arrhythmogenic activities of Mequitazine. | Approved |
| Mesoridazine | The risk or severity of adverse effects can be increased when Mesoridazine is combined with Lurasidone. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone. | Approved |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone. | Approved |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Lurasidone. | Approved, Illicit |
| Methamphetamine | Lurasidone may decrease the stimulatory activities of Methamphetamine. | Approved, Illicit |
| Methapyrilene | The risk or severity of adverse effects can be increased when Methapyrilene is combined with Lurasidone. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Methaqualone is combined with Lurasidone. | Illicit, Withdrawn |
| Methocarbamol | The risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone. | Approved |
| Methotrimeprazine | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lurasidone. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Lurasidone. | Experimental |
| Methylphenidate | The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate. | Approved, Investigational |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lurasidone. | Approved |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone. | Approved, Investigational |
| Metyrosine | Lurasidone may increase the sedative activities of Metyrosine. | Approved |
| Midazolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone. | Approved, Illicit |
| Mifepristone | The serum concentration of Lurasidone can be increased when it is combined with Mifepristone. | Approved, Investigational |
| Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone. | Approved |
| Miglustat | The therapeutic efficacy of Miglustat can be decreased when used in combination with Lurasidone. | Approved |
| Milnacipran | The risk or severity of adverse effects can be increased when Milnacipran is combined with Lurasidone. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved, Investigational |
| Mirtazapine | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| Mitiglinide | The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Mitotane | The serum concentration of Lurasidone can be decreased when it is combined with Mitotane. | Approved |
| MMDA | Lurasidone may decrease the stimulatory activities of MMDA. | Experimental, Illicit |
| Moclobemide | The risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone. | Approved |
| Modafinil | The serum concentration of Lurasidone can be decreased when it is combined with Modafinil. | Approved, Investigational |
| Molindone | The risk or severity of adverse effects can be increased when Molindone is combined with Lurasidone. | Approved |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone. | Approved, Investigational |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved, Investigational |
| Nafcillin | The serum concentration of Lurasidone can be decreased when it is combined with Nafcillin. | Approved |
| Nalbuphine | The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone. | Approved |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone. | Approved, Investigational |
| Nateglinide | The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Nefazodone | The serum concentration of Lurasidone can be increased when it is combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir. | Approved |
| Netupitant | The serum concentration of Lurasidone can be increased when it is combined with Netupitant. | Approved |
| Nevirapine | The serum concentration of Lurasidone can be decreased when it is combined with Nevirapine. | Approved |
| Nilotinib | The serum concentration of Lurasidone can be increased when it is combined with Nilotinib. | Approved, Investigational |
| Nimodipine | The serum concentration of Nimodipine can be increased when it is combined with Lurasidone. | Approved |
| Nitrazepam | The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone. | Approved |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lurasidone. | Approved, Vet Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Lurasidone is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Normethadone. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Lurasidone is combined with Nortriptyline. | Approved |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone. | Approved, Investigational |
| Olaparib | The serum concentration of Lurasidone can be increased when it is combined with Olaparib. | Approved |
| Olopatadine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine. | Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Ondansetron is combined with Lurasidone. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Lurasidone is combined with Opium. | Approved, Illicit |
| Orphenadrine | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Osanetant is combined with Lurasidone. | Investigational |
| Osimertinib | The serum concentration of Lurasidone can be increased when it is combined with Osimertinib. | Approved |
| Oxazepam | The risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lurasidone. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lurasidone. | Approved |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone. | Approved, Investigational, Vet Approved |
| Palbociclib | The serum concentration of Lurasidone can be increased when it is combined with Palbociclib. | Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone. | Approved |
| Paraldehyde | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Paroxetine | The risk or severity of adverse effects can be increased when Paroxetine is combined with Lurasidone. | Approved, Investigational |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone. | Approved, Vet Approved |
| Pentobarbital | The serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital. | Approved, Vet Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Perazine. | Investigational |
| Perospirone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone. | Approved |
| Phenelzine | The risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone. | Approved |
| Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Lurasidone. | Approved, Withdrawn |
| Phenobarbital | The serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital. | Approved |
| Phentermine | Lurasidone may decrease the stimulatory activities of Phentermine. | Approved, Illicit |
| Phenytoin | The serum concentration of Lurasidone can be decreased when it is combined with Phenytoin. | Approved, Vet Approved |
| Pimozide | The serum concentration of Pimozide can be increased when it is combined with Lurasidone. | Approved |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Pipamperone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine. | Approved |
| Piribedil | The therapeutic efficacy of Piribedil can be decreased when used in combination with Lurasidone. | Investigational |
| Piritramide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Piritramide. | Investigational |
| Pomalidomide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide. | Approved |
| Posaconazole | The serum concentration of Lurasidone can be increased when it is combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Pramipexole | Lurasidone may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine. | Approved |
| Prazepam | The risk or severity of adverse effects can be increased when Prazepam is combined with Lurasidone. | Approved, Illicit |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Lurasidone. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Prilocaine is combined with Lurasidone. | Approved |
| Primidone | The serum concentration of Lurasidone can be decreased when it is combined with Primidone. | Approved, Vet Approved |
| Procainamide | Lurasidone may increase the QTc-prolonging activities of Procainamide. | Approved |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with Lurasidone. | Approved, Investigational, Vet Approved |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone. | Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone. | Approved, Vet Approved |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone. | Approved, Vet Approved |
| Promethazine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Promethazine. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Proparacaine is combined with Lurasidone. | Approved, Vet Approved |
| Propofol | The risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Propoxycaine. | Approved |
| Protriptyline | The risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline. | Approved |
| Pseudoephedrine | Lurasidone may decrease the stimulatory activities of Pseudoephedrine. | Approved |
| Quazepam | The risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone. | Approved, Illicit |
| Quetiapine | The risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone. | Approved |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Lurasidone. | Approved |
| Quinidine | Lurasidone may increase the QTc-prolonging activities of Quinidine. | Approved |
| Raclopride | The risk or severity of adverse effects can be increased when Lurasidone is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon. | Approved, Investigational |
| Ranolazine | The serum concentration of Lurasidone can be increased when it is combined with Ranolazine. | Approved, Investigational |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone. | Approved |
| Remoxipride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Lurasidone. | Approved, Withdrawn |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone. | Approved |
| Rifabutin | The serum concentration of Lurasidone can be decreased when it is combined with Rifabutin. | Approved |
| Rifampicin | The serum concentration of Lurasidone can be decreased when it is combined with Rifampicin. | Approved |
| Rifapentine | The serum concentration of Lurasidone can be decreased when it is combined with Rifapentine. | Approved |
| Risperidone | The risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ritanserin. | Investigational |
| Ritobegron | Lurasidone may decrease the stimulatory activities of Ritobegron. | Investigational |
| Ritonavir | The serum concentration of Lurasidone can be increased when it is combined with Ritonavir. | Approved, Investigational |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone. | Approved |
| Ropinirole | Lurasidone may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone. | Approved |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Rotigotine | Lurasidone may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone. | Approved |
| Saquinavir | The serum concentration of Lurasidone can be increased when it is combined with Saquinavir. | Approved, Investigational |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone. | Approved |
| Scopolamine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine. | Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone. | Approved, Vet Approved |
| Selegiline | The risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone. | Approved, Investigational, Vet Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Sertindole is combined with Lurasidone. | Approved, Withdrawn |
| Sertraline | The risk or severity of adverse effects can be increased when Sertraline is combined with Lurasidone. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone. | Approved, Vet Approved |
| Sildenafil | The serum concentration of Lurasidone can be increased when it is combined with Sildenafil. | Approved, Investigational |
| Siltuximab | The serum concentration of Lurasidone can be decreased when it is combined with Siltuximab. | Approved |
| Simeprevir | The serum concentration of Lurasidone can be increased when it is combined with Simeprevir. | Approved |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Sodium oxybate | Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved |
| St. John's Wort | The serum concentration of Lurasidone can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Stiripentol | The serum concentration of Lurasidone can be increased when it is combined with Stiripentol. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone. | Approved, Investigational |
| Sulfisoxazole | The serum concentration of Lurasidone can be increased when it is combined with Sulfisoxazole. | Approved, Vet Approved |
| Sulodexide | The therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Sulpiride | The risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride. | Approved |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone. | Approved, Investigational |
| Suvorexant | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tandospirone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon. | Approved |
| Tedizolid Phosphate | The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone. | Approved |
| Telaprevir | The serum concentration of Lurasidone can be increased when it is combined with Telaprevir. | Withdrawn |
| Telithromycin | The serum concentration of Lurasidone can be increased when it is combined with Telithromycin. | Approved |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone. | Approved |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lurasidone. | Investigational |
| Thalidomide | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Thiamylal | The risk or severity of adverse effects can be increased when Thiamylal is combined with Lurasidone. | Approved, Vet Approved |
| Thiopental | The risk or severity of adverse effects can be increased when Thiopental is combined with Lurasidone. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone. | Withdrawn |
| Thiothixene | The risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride. | Approved, Investigational |
| Ticlopidine | The serum concentration of Lurasidone can be increased when it is combined with Ticlopidine. | Approved |
| Tizanidine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine. | Approved |
| Tocilizumab | The serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab. | Approved |
| Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone. | Approved |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone. | Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone. | Approved, Withdrawn |
| Topiramate | The risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate. | Approved |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone. | Approved, Investigational |
| Trans-2-Phenylcyclopropylamine | The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lurasidone. | Experimental |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone. | Approved |
| Trazodone | The risk or severity of adverse effects can be increased when Trazodone is combined with Lurasidone. | Approved, Investigational |
| Triazolam | The risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone. | Approved |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone. | Approved |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Lurasidone. | Approved, Vet Approved |
| Trimipramine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine. | Approved |
| Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lurasidone. | Withdrawn |
| Valproic Acid | The risk or severity of adverse effects can be increased when Valproic Acid is combined with Lurasidone. | Approved, Investigational |
| Venlafaxine | The serum concentration of Lurasidone can be increased when it is combined with Venlafaxine. | Approved |
| Verapamil | The serum concentration of Lurasidone can be increased when it is combined with Verapamil. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Lurasidone is combined with Vigabatrin. | Approved |
| Vilazodone | The risk or severity of adverse effects can be increased when Vilazodone is combined with Lurasidone. | Approved |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Voglibose | The therapeutic efficacy of Voglibose can be decreased when used in combination with Lurasidone. | Approved, Investigational |
| Voriconazole | The serum concentration of Lurasidone can be increased when it is combined with Voriconazole. | Approved, Investigational |
| Vortioxetine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine. | Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide. | Approved |
| Zimelidine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine. | Withdrawn |
| Ziprasidone | The serum concentration of Lurasidone can be increased when it is combined with Ziprasidone. | Approved |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone. | Approved, Investigational |
| Zolpidem | Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Zopiclone is combined with Lurasidone. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Lurasidone is combined with Zotepine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone. | Approved, Investigational |
